IONS - Ionis Pharmaceuticals, Inc.
About Ionis Pharmaceuticals, Inc. (https://www.ionispharma.com)
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brett Monia | Founder, Chief Executive Officer & Director | 1961 | $3,467,834 USD |
| Elizabeth L. Hougen | Executive Vice President of Finance & Chief Financial Officer | 1962 | $1,604,674 USD |
| Richard S. Geary | Strategic Consultant | 1958 | $1,331,792 USD |
| Brian Birchler | Executive Vice President of Corporate & Development Operations | 1966 | $1,240,447 USD |
| Eric E. Swayze | Executive Vice President of Research | 1966 | $1,233,732 USD |
| Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 | $1,211,001 USD |
| Kyle Jenne | Executive Vice President & Chief Global Product Strategy Officer | 1977 | $804,966 USD |
| C. Frank Bennett | Executive Vice President & Chief Scientific Officer | 1957 | $651,639 USD |
| Charles G. Asare | Vice President & Head of Drug Safety | – | – |
| Cliff Ford | Senior VP of Intellectual Property | – | – |
| D. Wade Walke | Senior Vice President of Investor Relations | – | – |
| Darren Gonzales | Chief Accounting Officer & Senior Vice President | – | – |
| Eugene Schneider | Executive Vice President, Chief Clinical Development & Operations Officer | 1973 | – |
| Hala Mirza | Senior Vice President of Corporate Affairs & Patient Advocacy | – | – |
| Jonathan J. Birchall | Senior VP & Chief Commercial Officer | 1970 | – |
| Rachel Carnes | Senior Vice President of Global Product Strategy | – | – |
| Roger Lane | Senior Vice President of Clinical Development | – | – |
| Sujit K. Basu | Vice President & Head of Pharmaceutical Development | – | – |
| Tracy Berns | Senior Vice President and Chief Compliance & Quality Assurance Officer | – | – |